Dr. Michelle Echevarria is an Assistant Member in the Department of Radiation Oncology. Dr. Echevarria received her Medical Degree at Ponce School of Medicine, Ponce, Puerto Rico, and her Master of Science in Molecular Medicine at the University of South Florida. Dr. Echevarria recently completed a Radiation Oncology Residency at Moffitt Cancer Center/University of South Florida, where she also served as Chief Resident. Dr. Echevarria’s clinical interests include the use of advanced radiation techniques such as intensity modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) in the treatment of head and neck cancers. Her research interests include the use of liquid biopsies, in the form of circulating tumor DNA and circulating viral DNA, as a personalization tool for the treatment of patients with head and neck cancer.
Echevarria M, Caudell J. Balancing Risks and Benefits of Dose and Volume of Radiation Therapy in a Neck Recurrence From Tongue Cancer. Int J Radiat Oncol Biol Phys. 2020 Apr.106(5):902-903. Pubmedid: 32171458.
Martin-Gomez L, Giuliano AR, Fulp WJ, Caudell J, Echevarria M, Sirak B, Abrahamsen M, Isaacs-Soriano KA, Hernandez-Prera JC, Wenig BM, Vorwald K, McMullen CP, Wadsworth JT, Slebos RJ, Chung CH. Human Papillomavirus Genotype Detection in Oral Gargle Samples Among Men With Newly Diagnosed Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngol Head Neck Surg. 2019 May.145(5):460-466. Pubmedid: 30920604. Pmcid: PMC6537790.
Echevarria MI, Awasthi S, Cheng CH, Berglund AE, Rounbehler RJ, Gerke TA, Takhar M, Davicioni E, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Den RB, Cleveland JL, Park JY, Rayford W, Yamoah K. African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. J Urol. 2019 Aug.202(2):247-255. Pubmedid: 31107158. Pmcid: PMC7882398.
Naghavi AO, Echevarria MI, Strom TJ, Abuodeh YA, Venkat PS, Ahmed KA, Demetriou S, Frakes JM, Kim Y, Kish JA, Russell JS, Otto KJ, Chung CH, Harrison LB, Trotti A, Caudell JJ. Patient choice for high-volume center radiation impacts head and neck cancer outcome. Cancer Med. 2018 Oct.7(10):4964-4979. Pubmedid: 30175512. Pmcid: PMC6198196.
Frakes JM, Abuodeh YA, Naghavi AO, Echevarria MI, Shridhar R, Friedman M, Kim R, El-Haddad G, Kis B, Biebel B, Sweeney J, Choi J, Anaya D, Giuliano AR, Hoffe SE. Viral hepatitis associated hepatocellular carcinoma outcomes with yttrium-90 radioembolization. J Gastrointest Oncol. 2018 Jun.9(3):546-552. Pubmedid: 29998020. Pmcid: PMC6006034.
Abuodeh Y, Naghavi AO, Echevarria M, DeMarco M, Tonner B, Feygelman V, Stevens CW, Perez BA, Dilling TJ. Quantitatively Excessive Normal Tissue Toxicity and Poor Target Coverage in Postoperative Lung Cancer Radiotherapy Meta-analysis. Clin Lung Cancer. 2018 Jan.19(1):e123-e130. Pubmedid: 29107487.
Echevarria MI, Naghavi AO, Abuodeh YA, Ahmed KA, Chevere C, Fernandez D, Yamoah K. Low-dose-rate Brachytherapy for Prostate Cancer in Low-resource Settings. Int J Radiat Oncol Biol Phys. 2017 Oct.99(2):378-382. Pubmedid: 28871987.
Naghavi AO, Gonzalez RJ, Scott JG, Kim Y, Abuodeh YA, Strom TJ, Echevarria M, Mullinax JE, Ahmed KA, Harrison LB, Fernandez DC. Staged reconstruction brachytherapy has lower overall cost in recurrent soft-tissue sarcoma. J Contemp Brachytherapy. 2017 Feb.9(1):20-29. Pubmedid: 28344600. Pmcid: PMC5346606.
Abuodeh Y, Ahmed K, Echevarria M, Naghavi A, Grass GD, Robinson TJ, Tomblyn M, Shah B, Chavez J, Bello C, El-Haddad G, Harrison L, Kim S. Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma. Ther Adv Hematol. 2017 Apr.8(4):129-138. Pubmedid: 28491264. Pmcid: PMC5405899.
Echevarria MI, Naghavi AO, Venkat PS, Abuodeh YA, Chevere C, Yamoah K. The impact of body mass index on dosimetric quality in low-dose-rate prostate brachytherapy. J Contemp Brachytherapy. 2016 Oct.8(5):386-390. Pubmedid: 27895679. Pmcid: PMC5116453.
Naghavi AO, Echevarria MI, Grass GD, Strom TJ, Abuodeh YA, Ahmed KA, Kim Y, Trotti AM, Harrison LB, Yamoah K, Caudell JJ. Having Medicaid insurance negatively impacts outcomes in patients with head and neck malignancies. Cancer. 2016 Nov.122(22):3529-3537. Pubmedid: 27479362. Pmcid: PMC7810134.
Naghavi AO, Strom TJ, Ahmed KA, Echevarria MI, Abuodeh YA, Venkat PS, Frakes JM, Harrison LB, Trotti AM, Caudell JJ. Management of Oropharyngeal Cancer in the HPV Era. Cancer Control. 2016 Jul.23(3):197-207. Pubmedid: 27556659.
Ahmed KA, Abuodeh YA, Echevarria MI, Arrington JA, Stallworth DG, Hogue C, Naghavi AO, Kim S, Kim Y, Patel BG, Sarangkasiri S, Johnstone PA, Sahebjam S, Khushalani NI, Forsyth PA, Harrison LB, Yu M, Etame AB, Caudell JJ. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Ann Oncol. 2016 Dec.27(12):2288-2294. Pubmedid: 27637745.
Naghavi AO, Echevarria MI, Strom TJ, Abuodeh YA, Ahmed KA, Venkat PS, Trotti A, Harrison LB, Green BL, Yamoah K, Caudell JJ. Treatment delays, race, and outcomes in head and neck cancer. Cancer Epidemiol. 2016 Dec.45:18-25. Pubmedid: 27664388.
Eschrich SA, Fulp WJ, Pawitan Y, Foekens JA, Smid M, Martens JW, Echevarria M, Kamath V, Lee JH, Harris EE, Bergh J, Torres-Roca JF. Validation of a radiosensitivity molecular signature in breast cancer. Clin Cancer Res. 2012 Sep.18(18):5134-5143. Pubmedid: 22832933. Pmcid: PMC3993974.
The Provider Rating is an average of all responses to specific care provider-related
questions from our nationally-recognized
Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our
Patient Satisfaction Survey . The comments are submitted by patients
and reflect their views and opinions. Patients are de-identified for confidentiality and
We post both positive and negative comments from the surveys. We do not post comments
that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may
risk the privacy of our patients.
A “[…]” in the comments below indicates de-identified patient information or comments that
are unrelated to the patient’s experience with the visit to the provider, such as
comments related to another provider, about the survey itself, or otherwise completely
Not all providers will have a star rating or comments. In order to ensure accuracy of our
ratings, we only display ratings for providers who have a minimum of 30 completed from
the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey
Patient Satisfaction Survey. If a provider does not have ratings or comments listed it
can be for several reasons, including:
The provider has not yet received the minimum number of patient satisfaction surveys
to be eligible for display. We require a minimum of 30 surveys before we post
results to ensure that the rating is statistically reliable and a true reflection of
He or she may be a researcher or other type of provider that does not see patients.
The provider practices in a specialty or office that does not use the specified
surveys currently used for these ratings.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub